Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 267,594 | 195,992 | 151,862 | 316,613 | 146,691 |
| Cost of Goods | 43,367 | 45,546 | 10,136 | 31,152 | 33,206 |
| Gross Profit | 224,227 | 150,446 | 141,726 | 285,461 | 113,485 |
| Operating Expenses | 80,339 | 218,602 | 211,192 | 204,611 | 196,901 |
| Operating Income | 144,255 | -67,610 | -69,330 | 81,002 | -83,210 |
| Interest Expense | 20,378 | 11,627 | 18,041 | 21,984 | 19,977 |
| Other Income | 5,425 | 6,986 | 7,578 | 2,592 | 1,326 |
| Pre-tax Income | 129,302 | -72,251 | -79,793 | 61,610 | -101,861 |
| Income Tax | 217 | -11 | 537 | -1,361 | 1,162 |
| Net Income Continuous | 129,085 | -72,240 | -80,330 | 62,971 | -103,023 |
| Net Income | $129,085 | $-72,240 | $-80,330 | $62,971 | $-103,023 |
| EPS Basic Total Ops | 0.95 | -0.50 | -0.56 | 0.46 | -0.81 |
| EPS Basic Continuous Ops | 0.95 | -0.50 | -0.56 | 0.46 | -0.81 |
| EPS Diluted Total Ops | 0.91 | -0.50 | -0.56 | 0.45 | -0.81 |
| EPS Diluted Continuous Ops | 0.91 | -0.50 | -0.56 | 0.45 | -0.81 |
| EPS Diluted Before Non-Recurring Items | 0.91 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $162,514 | $-63,527 | $-68,487 | $84,621 | $-67,616 |